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Aims: Endothelin-1 contributes to endothelial dysfunction in patients with atherosclerosis and type 2 diabetes. In
healthy arteries the ETA receptor mediates the main part of the vasoconstriction induced by endothelin-1 whilst
the ETB receptor mediates vasodilatation. The ETB receptor expression is upregulated on vascular smoothmuscle
cells in atherosclerosis andmay contribute to the increased vasoconstrictor tone and endothelial dysfunction ob-
served in this condition. Due to these opposing effects of the ETB receptor it remains unclear whether ETB block-
ade togetherwith ETA blockademay be detrimental or beneﬁcial. The aimwas therefore to compare the effects of
selective ETA and dual ETA/ETB blockade on endothelial function in patients with type 2 diabetes and coronary
artery disease.
Main methods: Forearm endothelium-dependent and endothelium-independent vasodilatation was assessed
by venous occlusion plethysmography in 12 patients before and after selective ETA or dual ETA/ETB receptor
blockade.
Key ﬁndings: Dual ETA/ETB receptor blockade increased baseline forearm blood ﬂow by 30 ± 14% (P b 0.01)
whereas selective ETA blockade did not (14± 8%). Both selective ETA blockade and dual ETA/ETB blockade signif-
icantly improved endothelium-dependent vasodilatation. The improvement did not differ between the two
treatments. There was also an increase in endothelium-independent vasodilatation with both treatments. Dual
ETA/ETB blockade did not signiﬁcantly increase microvascular ﬂow but improved transcutaneous pO2.
Signiﬁcance: Both selective ETA and dual ETA/ETB improve endothelium-dependent vasodilatation in patients
with type 2 diabetes and coronary artery disease. ETB blockade increases basal blood ﬂow but does not addition-
ally improve endothelium-dependent vasodilatation.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Diabetes mellitus is associated with a considerable risk for cardio-
vascular complications such as peripheral arterial disease, coronary ar-
tery disease and myocardial infarction (Moreno and Fuster, 2004).
There are observations suggesting that endothelial dysfunction plays
an important role in the early development of vascular complications
in diabetes (Creager et al., 2003). Presence of endothelial dysfunction
is also an independent risk factor for future cardiovascular events in pa-
tients with coronary artery disease (Lerman and Zeiher, 2005). Endo-
thelial dysfunction is characterized by reduced bioavailability of the
vasodilator and anti-inﬂammatorymolecule nitric oxide. Another factor
of potential importance for endothelial dysfunction in type 2 diabetes is
endothelin-1 (ET-1) which exerts potent vasoconstrictor and pro-y, Landspítali 101 Reykjavík,
. This is an open access article underinﬂammatory actions via activation of the two receptors, ETA and ETB.
Both receptors are present on vascular smooth muscle cells mediating
vasoconstriction, whilst the ETB receptor is also present on endothelial
cells mediating vasodilatation. Elevated levels of ET-1 are found in pa-
tients with type 2 diabetes (Takahashi et al., 1990). Due to the dynamics
of the expression and function of the two ET receptors described above,
the effect of ET receptor blockade may vary depending on the type and
stage of pathological condition. Whilst the ETA receptor inevitably
causes vasoconstriction and exerts pro-oxidative actions, ETB receptor
stimulation may cause vasodilatation in healthy subjects due to the
stimulation of NO production or it may cause vasoconstriction in pa-
tients with atherosclerosis due to upregulation of the ETB receptor on
vascular smooth muscle cells (Pernow et al., 2012). The potential bene-
ﬁcial or detrimental effect of dual ETA/ETB receptor blockade in compar-
isonwith selective ETA receptor blockade has therefore been amatter of
much discussion. A recent clinical study demonstrated that the dual ET
receptor antagonist bosentan improves microvascular endothelial func-
tion in patients with type 2 diabetes which suggests beneﬁcial effect ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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comparison between selective and dual receptor blockade in patients
with coronary artery disease and type 2 diabetes has to the best of our
knowledge not been performed. It therefore is of importance in detail
to clarify the effect of selective ETA vs. dual ETA/ETB receptor blockade
on endothelial function in patients with type 2 diabetes and vascular
complications. The hypothesis was that dual ETA/ETB results in greater
vasodilator effect and improvement in endothelium-dependent vasodi-
latation than selective ETA receptor blockade.
Materials and methods
Patients
Patients with type 2 diabetes of at least two years duration and
known coronary artery disease were recruited from the Department of
Cardiology, during follow-up after coronary revascularization. The re-
cruitment period was from August 2012 to January 2013. Patients
were classiﬁed as having diabetes mellitus if fasting blood glucose
exceeded 6.0 mmol/L (on at least two occasions) or blood glucose con-
centration was N11.0 mmol/L after an oral glucose loading (75 mg).
Coronary artery disease was deﬁned as either previous coronary artery
bypass surgery (CABG) or percutaneous coronary intervention (PCI)
with stenting. Exclusion criteria were myocardial infarction or unstable
angina within the last six weeks, known Raynaud's phenomenon, pe-
ripheral vasculopathies, arterial shunting or other vascular surgery of
the study arm, change in dose of any vasodilator drug during the pre-
ceding six weeks, ongoing treatment with warfarin or concomitant dis-
ease that may have interfered with the possibility for the patients to
comply with or complete the study protocol. The study protocol was
conducted according to the Declaration of Helsinki and was approved
by the regional Ethics Committee in Stockholm. Written informed con-
sent was obtained from all patients.
Study design
The study was a single blinded study with blinded evaluation.
Twelve patients were included in the study. On the day of the study
the subject arrived to the laboratory after an overnight fasting period.
After collection of baseline blood samples (see below) the patients
were given a light breakfast consisting of a cheese sandwich and juice.
The patients were instructed not to take any tobacco containing prod-
ucts or their morning medication. The study was based on a cross-
over protocol and the patients were investigated on two occasions sep-
arated by at least one week. A percutaneous catheter was under local
anaesthesia inserted in the brachial artery of the non-dominant
arm for infusions and collection of blood samples. Another catheter
was inserted in a deep cubital vein of the ipsilateral arm for blood sam-
pling. Ononeof the study occasions thepatientswere randomized to re-
ceive intra-arterial infusion of the ETA receptor antagonist BQ123
(10 nmol/min) (selective blockade) and on the other occasion a combi-
nation of BQ123 and the ETB receptor antagonist BQ788 (5 nmol/min)
(dual blockade) for 60 min. The doses of the antagonists were based
on previous experience (Shemyakin et al., 2006).
Venous occlusion plethysmography
Forearm blood ﬂow was measured simultaneously in both arms
with venous occlusion plethysmography using the mercury-in-silastic
strain-gauge technique. A venous occlusion cuff placed around the
upper armwas inﬂated to 40mmHg for 10 s to obtain recordings of ar-
terial inﬂow followed by deﬂation for 5 s. During recordings of blood
ﬂow the circulation of the hands was occluded by a cuff inﬂated to
30 mm Hg above systolic blood pressure.
The investigations were performed with the patient in the supine
position in a temperature controlled environment (22 ± 1 °C).Endothelium-dependent vasodilatation was determined by intra-
arterial infusion of serotonin (21, 70 and 210 ng/min). Endothelium-
independent vasodilatation was determined by intra-arterial infusion
of sodium nitroprusside (SNP; 1, 3 and 10 μg/min). Each dose was
given for 2 min at a rate of 2.5 mL/min. Endothelium-dependent
and -independent vasodilatation was determined at baseline and at
the end of the 60min infusions of the ET receptor antagonists. The nitric
oxide-dependent property of the vasodilatation induced by serotonin
in this patient group has previously been validated in this model by
our group (Shemyakin et al., 2012).
Laser Doppler ﬂuxmetry
Skin microcirculation was evaluated with laser Doppler ﬂuxmetry
(LDF, Periﬂux 5000 system, Perimed, Sweden) on the forearm distal to
the plethysmograph strain gauge. The site was photographed in order
to place the probe in exactly the same location between the visits. The
unit measured is called perfusion units (PU) and represents total
blood ﬂow in the measured area. The signal was continuously recorded
during the experiment and after conclusion of the occlusion plethys-
mography, local thermal hyperemia LDF was measured after at least
15min of heating to 44 °C. Thereby forearm skinmicrovascular ﬂowbe-
fore and during the infusion of either BQ123 alone or BQ123 + BQ788
was determined.
Transcutaneous oxygen tension (tcpO2)
A transcutaneous (tc) pO2 probe (PF 5040, Perimed, Sweden)was at-
tached to the forearm in the beginning of the study protocol for continu-
ous recording. Readout of themeasurementwas done both before and at
the end of the infusions of antagonists in a standardized fashion and a
photograph was taken as described above. The measured unit is mm Hg.
Laboratory investigations
Screening blood samples were taken on themorning of the ﬁrst visit
for analysis of blood glucose, HbA1C, total cholesterol, low-density lipo-
protein cholesterol, high-density lipoprotein cholesterol, triglycerides,
C-reactive protein, creatinine, IGF-1 and IGFBP-1. Plasma ET-1 levels
were measured by chemiluminescent immunoassay ELISA (Quantiglo
kit, R&D, Abingdon, UK) before and after completion of the treatment
protocol. Estimated glomerular ﬁltration rate (eGFR) was calculated
using the Cockroft-Gault formula.
Statistical analysis
Data are presented asmeans± SEMexcept clinical characteristics of
the patients which are presented as means ± SD. Baseline FBF was cal-
culated as themean of 4 to 8 inﬂow recordings during 2min. During the
vasodilator response to serotonin and SNP, the 4 highest ﬂow record-
ings at the end of the infusionwere used for calculations. Because no in-
fusions affected blood pressure or contralateral forearm blood ﬂow, all
hemodynamic effects mediated by serotonin and SNP are expressed as
absolute blood ﬂow changes from baseline blood ﬂow during infusion
of saline. Differences in forearm blood ﬂow change in response to differ-
ent doses of serotonin and SNP between the two different treatments
were assessed by 2-way analysis of variance. Changes in baseline ﬂow
were assessed by 1-way repeated-measures analysis of variance
followed by the Bonferroni multiple comparison test. Differences in
basal ﬂow between the groups were assessed by 2-way analysis
of variance with the Bonferroni multiple comparison test. A value
of P b 0.05 was considered signiﬁcant. Based on a previous study per-
formed using a similar study protocol we have observed improve-
ment in endothelium-dependent vasodilatation by 30% following
dual receptor blockade (Settergren et al., 2008a). Assuming similar
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be 12 (α= 0.05 and 80% power).
Results
Study subjects
The patient characteristics are presented in Table 1. Blood pres-
sure or heart rate did not change during the infusions of the ET re-
ceptor antagonists. No adverse effects occurred during any of the
experiments.
Venous occlusion plethysmography
There was no signiﬁcant difference in baseline forearm blood ﬂow
between the two study occasions. Dual ETA/ETB receptor blockade
with the combined infusion of BQ123 and BQ788 resulted in an increase
in baseline ﬂow from 36.4± 2.7 to 47.6± 4.2 mL/min/1000mLwhere-
as selective ETA receptor blockade did not increase baseline ﬂow signif-
icantly (37.5 ± 3.0 vs. 42.1 ± 2.5 mL/min/1000 mL). Endothelium-
dependent vasodilatation induced by serotonin was signiﬁcantly
increased by both selective ETA blockade and dual receptor blockade
(Fig. 1A–B). The effect of the two treatment strategies was similar
(Fig. 1C). Both treatments also increased the endothelium-independent
vasodilatation induced by SNP (Fig. 1D–E).
Laser Doppler ﬂuxmetry
Administration of BQ123 signiﬁcantly increased microvascular ﬂow
measured with laser Doppler ﬂuxmetry (Fig. 2A). A similar trend was
observed with the combined administration of BQ123 + BQ788 but
this change did not reach statistical signiﬁcance. There was no differ-
ence in the response to heat challenge between the two treatments,
1326± 115% increase during selective blockade and 1459± 214% dur-
ing dual blockade (P = 0.47).Table 1
Baseline characteristics (mean ± SD).
Characteristics n = 12
Age, years 64.8 ± 9.0
Height, cm 175 ± 5
Weight, kg 87.8 ± 10.9
BMI, kg/m2 28.4 ± 2.3
Hip–waist ratio 1.0 ± 0.04
Glucose, mmol/L 8.4 ± 1.9
HbA1c, mmol/mol 57.8 ± 8.0
Creatinine, μmol/L 84 ± 16
eGFR, mL/min 99 ± 21
Haemoglobin, g/L 144 ± 13
C-reactive protein, mg/L 2.1 ± 2.0
Triglycerides, mmol/L 1.7 ± 1.0
Cholesterol, mmol/L 4.2 ± 1.0
HDL cholesterol, mmol/L 1.2 ± 0.4
LDL cholesterol, mmol/L 2.2 ± 0.9
Systolic BP, mm Hg 138 ± 13
Diastolic BP, mm Hg 75 ± 12
Treatment
Aspirin, n 10
Oral antidiabetic agent, n 10
Insulin, n 6
Betablocker, n 7
Nitrates, long acting, n 2
ACEi/ARB, n 9
Calcium channel blocker, n 9
Statin, n 10
Other antihypertensive treatment, n 2
BMI = body mass index, HbA1c = glycosylated haemoglobin, eGFR =
estimated glomerular ﬁltration rate. ACEi = angiotensin converting enzyme
inhibitor, ARB = angiotensin receptor blocker.tcpO2
tcpO2 did not change signiﬁcantly during administration of BQ123
whereas it increased signiﬁcantly during the administration of
BQ123 + BQ788 (Fig. 2B).
Biochemical analyses
The baseline values of blood analyses are shown in Table 1. Arterial
plasma ET-1 increased after administration of BQ123 + BQ788
from 0.96 ± 0.14 to 1.75 ± 0.27 pg/mL (P b 0.01) whereas it was not
changed by administration of BQ123 alone, 0.96 ± 0.18 to 1.1 ±
0.18 pg/mL.
Discussion
The main ﬁnding of the present study is that selective ETA and dual
ETA/ETB receptor blockade markedly improve endothelium-dependent
vasodilatation in patients with type 2 diabetes and vascular complica-
tions. The magnitude of improvement did not differ between the two
treatment strategies. The results suggest that addition of ETB blockade
to ETA blockade does not provide additional beneﬁcial effects on endo-
thelial function in this patient group.
Previous studies have demonstrated that ET-1 is of importance for
the development of endothelial dysfunction. ET receptor blockade
does not affect endothelium-dependent vasodilatation in healthy sub-
jects (Shemyakin et al., 2006). In subjects with insulin-resistance but
without cardiovascular disease, it was shown that dual ETA/ETB block-
ade but not selective ETA blockade improved endothelial function
(Shemyakin et al., 2006). This observationwas supported by the ﬁnding
that the dual antagonist bosentan improved peripheral endothelial
function in patients with type 2 diabetes and microvascular complica-
tions (Rafnsson et al., 2012). On the other hand, a recent study demon-
strated that 6 months treatment with the oral ETA receptor antagonist
atrasentan improved coronary endothelial function in patients with
atherosclerosis (Reriani et al., 2010). The current study is to the best
of our knowledge the ﬁrst to directly compare the effect of selective
ETA with dual ETA/ETB receptor blockade on patients with developed
cardiovascular diseases. There was no difference between the two dif-
ferent treatment strategies meaning that both selective ETA and dual
ETA/ETB inhibition were equally effective in improving endothelium-
dependent vasodilatation in patients with type 2 diabetes and coronary
artery disease. The observation is important due to the concern that
blockade of ETB receptors on endothelial cells may impair release of ni-
tric oxide and thereby endothelium-dependent vasodilatation. Such an
effect does not seem to be of functional relevance in the present patient
group which has markedly impaired bioavailability of NO (Shemyakin
et al., 2012). Efﬁcient blockade of the ETB receptor (clearance receptor)
was conﬁrmed by the ﬁnding that plasma ET-1 levels increased only fol-
lowing dual ETA/ETB receptor blockade. Collectively our data show that
dual ETA/ETB receptor blockade seems to improve endothelial function
as efﬁciently as selective ETA blockade.
In addition to improving endothelium-dependent vasodilatation,
dual ETA/ETB blockade signiﬁcantly increased baseline forearm blood
ﬂow, whereas selective ETA blockade did not. This observation is in
line with the previous demonstration that vascular smooth muscle cell
expression of ETB receptors is upregulated in atherosclerosis and in
type two diabetes (Pernow et al., 2012; Iwasa et al., 1999; Li et al.,
2011). Such upregulation may explain an increase in vascular tone me-
diated by the ETB receptor. The clinical signiﬁcance of a reduced vascular
tonemediated by dual receptor blockade is unknownbut theoretically it
might have a long term effect by reducing arterial stiffness and thus re-
ducing secondary vascular complications of diabetes. Furthermore, dual
ET receptor blockade has been demonstrated to increase insulin sensi-
tivity in patients with insulin resistance (Shemyakin et al., 2010).
Fig. 1. Endothelium-dependent vasodilatation (A–C) and endothelium-independent vasodilatation (D–F) determined as change in forearm blood ﬂow (FBF) induced by serotonin and
SNP, respectively. A and D: Before and during infusion of BQ123. B and E: Before and during infusion of BQ123 + BQ788. C and F: Change from baseline comparing the effect of the
two treatments. Data are given as means and SEM. Signiﬁcant differences from the responses to serotonin and SNP at baseline are given.
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endothelium-independent vasodilatation induced by SNP. Previous
studies using ET receptor blockade and other interventions aiming at in-
creasing nitric oxide bioavailability have demonstrated that not only
endothelium-dependent but also endothelium-independent vasodila-
tationwas increased in patients with type 2 diabetes but not in patients
without diabetes (Shemyakin et al., 2006, 2012, 2011). These observa-
tions suggest an effect on vascular smoothmuscle cells or increased bio-
availability also of exogenously administered NO among this patient
group.
Interestingly, selective ETA blockade increased cutaneous blood ﬂow
as measured by laser Doppler ﬂuxmetry. This is a measure of total blood
ﬂow in the different vessels in the skin including venules, capillaries as
well as arterioles. This ﬁnding is in accordance with the previous demon-
stration that selective ETA inhibition improves nutritive cutaneous capil-
lary ﬂow in patients with type 2 diabetes and albuminuria (Settergren
et al., 2008b). Although not signiﬁcant, there was a trend towards in-
creased laser Doppler ﬂow also with dual receptor blockade and clinical
studies have shown increased skin perfusion in patients with systemic
sclerosis treated with the dual receptor antagonist bosentan (Rosato
et al., 2010). The present study in addition demonstrates that dualFig. 2. (A) Cutaneousmicrovascular ﬂow and (B) Transcutaneous O2 tension at baseline and afte
*P b 0.05.receptor blockade signiﬁcantly increased tcpO2 suggesting improved
skin oxygenation. A similar trend is seen with selective ETA blockade
although not signiﬁcant. Further studies arewarranted to evaluate the ef-
ﬁcacy of ET receptor blockade on skin microvascular function in patients
with type 2 diabetes and cutaneous microvascular complications.
There are some limitations related to the study. First, the number of
study subjects is arguably small but there is no indication that the results
would have been any different with a larger study group. The effect of
dual receptor blockade on endothelium-dependent vasodilatation was
of the magnitude estimated the power estimation. Second, the method
chosen for the primary endpoint measures changes in endothelial func-
tion as a reaction to the infused substances and therefore reﬂect short
time changes in the vascular bed. There is a possibility that longer time
treatment with oral substances might elicit changes different from
those obtained in the present study. In support of our data is the obser-
vation that 4 week oral administration of the dual antagonist bosentan
improves peripheral endothelial function in patients with type 2 diabe-
tes (Rafnsson et al., 2012). Third, the secondary endpoint of change in
blood ﬂow of the skin measured by laser Doppler is dependent on
probe placement on different study occasions. Although care was taken
to ensure correct placement this is a limitation in the study design.r infusion of BQ123 and BQ123+ BQ788, respectively. Data are given as means and SEM.
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Both selective ETA and dual ETA/ETB receptor blockade increase
endothelium-dependent vasodilatation in patients with type 2 diabetes
and coronary artery disease. ETB blockade increases basal bloodﬂowbut
does not additionally improve endothelium-dependent vasodilation be-
yond that induced by selective ETA blockade. Importantly, however, it
does not attenuate the beneﬁcial effect of ETA receptor blockade on
endothelium-dependent vasodilatation in this patient group. This ob-
servation is of importance for future drug therapy aiming at improving
vascular function in patients with type 2 diabetes.
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